Free shipping on all orders over $ 500


Cat. No. M4830
LY2584702 Structure
Size Price Availability Quantity
5mg USD 80  USD80 In stock
10mg USD 129  USD129 In stock
50mg USD 450  USD450 In stock
100mg USD 750  USD750 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >98%
  • COA
  • MSDS
Biological Activity

LY2584702 inhibits ribosomal protein S6 Kinase (p70S6K), and prevents phosphorylation of the S6 subunit of ribosomes, thereby inhibiting normal ribosomal function within tumor cells leading to a decrease in protein synthesis and in cellular proliferation.LY2584702 exhibited anti-tumour activity in preclinical analysis.

Customer Product Validations & Biological Datas
Source PLoS One (2017). Figure 1. LY2584702
Method Isolation of human neutrophils and cell stimulations
Cell Lines human neutrophils cell
Concentrations 10 μM
Incubation Time 5 minutes
Results This led to a decrease in 20-OH- and 20-COOH-LTB4 levels, and an increase in LTB4 levels. In contrast, LY2584702 did not prevent the metabolism of LTB4 into 20-OH- and 20-COOH-LTB4 in thapsigargin-stimulated neutrophils
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 445.42
Formula C21H19F4N7
CAS Number 1082949-67-4
Purity >98%
Solubility DMSO > 4.5 mg/mL
Storage at -20°C

[1] Hollebecque A, et al. Eur J Cancer. A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.

[2] Tolcher A, et al. Eur J Cancer. A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours.

Related S6 Kinase Products
LY2584702 Tosylate

LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM.

SL 0101-1

SL-0101-1 is a selective p90 RSK inhibitor for RSK2 with IC50 of 89 nM.


FMK is a potent and selective inhibitor of p90 ribosomal protein S6 kinaseRSK2 (wt) with IC50 of 15 nM, >600- and 200-fold selectivity for RSK2 than the C436V and T493M mutants.


PF-4708671 is a novel cell-permeable inhibitor of S6K1 with Ki/IC50 value of 20 nM/160 nM.


BI-D1870 is a small molecule specific inhibitor of the p90 RSK (ribosomal S6 kinase) with an IC50 of 10-30 nM.

Abmole Inhibitor Catalog 2017

Keywords: LY2584702 supplier, S6 Kinase, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.